Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

AN2 Therapeutics, Inc. (ANTX) vs Coherus Oncology, Inc. (CHRS)

AN2 Therapeutics, Inc. and Coherus Oncology, Inc. are both Biotechnology companies. AN2 Therapeutics, Inc. and Coherus Oncology, Inc. are of similar size ($184.5M and $183.9M). AN2 Therapeutics, Inc. has the higher net margin (0.00% vs −259.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, AN2 Therapeutics, Inc. leads on 8 and Coherus Oncology, Inc. on 6.

Valuation

Metric ANTX CHRS Biotechnology median
P/E n/m n/m 7.88
P/S n/m 3.43 11.47
P/B 2.88 2.88 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 5.53 10.73
Earnings yield (21.93%) (91.15%) (28.84%)
Free cash flow yield (14.05%) (106.88%) (23.03%)

Profitability

Metric ANTX CHRS Biotechnology median
Gross margin 0.00% 68.94% 65.16%
Operating margin 0.00% (311.56%) 0.00%
Net margin 0.00% (259.41%) 0.00%
Free cash flow margin 0.00% (365.22%) 0.00%
Return on equity (50.12%) (146.27%) (57.72%)
Return on assets (46.06%) (41.90%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ANTX CHRS Biotechnology median
Revenue growth (TTM) — 61.00% 5.64%
EPS growth (last fiscal year) 32.56% 472.00% —
Revenue growth, 5-year CAGR — (38.41%) 8.40%
Net income growth, 5-year CAGR 0.00% 4.91% 0.00%

Health

Metric ANTX CHRS Biotechnology median
Debt to equity 0.00 0.61 0.00
Current ratio 14.32 1.77 4.73
Net debt to EBITDA 1.48 0.76 0.96

Dividend

Metric ANTX CHRS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ANTX CHRS Biotechnology median
Market cap 184.53m 183.86m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack